Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CLK1 | P49759 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16812493 | 0.90 | NR3C1 (0.39) | SMN1; SMN2TP53CLK1NR3C1MEN1 | |
| SCHEMBL16812355 | 0.90 | ALDH1A1 (0.39) | CDK5CDK5R1SMN1; SMN2NR3C1MEN1 | |
| SCHEMBL16812352 | 0.88 | PDE1B (0.38) | HPGDSMN1; SMN2NR3C1MEN1KMT2A | |
| SCHEMBL16812482 | 0.88 | NPC1 (0.40) | HPGDSMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL16812486 | 0.88 | NPC1 (0.40) | HPGDSMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL16794695 | 0.85 | TYK2 (0.44) | CLK1NR3C1MEN1KMT2APDE1B | |
| SCHEMBL16794714 | 0.85 | TYK2 (0.49) | CLK1NR3C1MEN1KMT2APDE1B | |
| SCHEMBL18161034 | 0.85 | PDE1B (0.41) | SMN1; SMN2NR3C1MEN1KMT2APDE1B | |
| SCHEMBL16794676 | 0.85 | PDE1B (0.40) | SMN1; SMN2NPC1RAB9ANR3C1MEN1 | |
| SCHEMBL20557571 | 0.85 | TYK2 (0.46) | CLK1NR3C1MEN1KMT2APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | TYK2, IFNAR1, JAK3 | CDK5 1098/4885CDK5R1 891/4885HPGD 2781/4885 |
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | TYK2, IFNG, IFNAR1 | CDK5 1089/4885CDK5R1 935/4885HPGD 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.